PMID- 23016149
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120928
LR  - 20211021
IS  - 2190-4286 (Electronic)
IS  - 2190-4286 (Linking)
VI  - 3
DP  - 2012
TI  - Magnetic-Fe/Fe(3)O(4)-nanoparticle-bound SN38 as carboxylesterase-cleavable 
      prodrug for the delivery to tumors within monocytes/macrophages.
PG  - 444-55
AB  - The targeted delivery of therapeutics to the tumor site is highly desirable in 
      cancer treatment, because it is capable of minimizing collateral damage. Herein, 
      we report the synthesis of a nanoplatform, which is composed of a 15 +/- 1 nm 
      diameter core/shell Fe/Fe(3)O(4) magnetic nanoparticles (MNPs) and the 
      topoisomerase I blocker SN38 bound to the surface of the MNPs via a 
      carboxylesterase cleavable linker. This nanoplatform demonstrated high heating 
      ability (SAR = 522 +/- 40 W/g) in an AC-magnetic field. For the purpose of targeted 
      delivery, this nanoplatform was loaded into tumor-homing double-stable RAW264.7 
      cells (mouse monocyte/macrophage-like cells (Mo/Ma)), which have been engineered 
      to express intracellular carboxylesterase (InCE) upon addition of doxycycline by 
      a Tet-On Advanced system. The nanoplatform was taken up efficiently by these 
      tumor-homing cells. They showed low toxicity even at high nanoplatform 
      concentration. SN38 was released successfully by switching on the Tet-On Advanced 
      system. We have demonstrated that this nanoplatform can be potentially used for 
      thermochemotherapy. We will be able to achieve the following goals: (1) 
      Specifically deliver the SN38 prodrug and magnetic nanoparticles to the cancer 
      site as the payload of tumor-homing double-stable RAW264.7 cells; (2) Release of 
      chemotherapeutic SN38 at the cancer site by means of the self-containing Tet-On 
      Advanced system; (3) Provide localized magnetic hyperthermia to enhance the 
      cancer treatment, both by killing cancer cells through magnetic heating and by 
      activating the immune system.
FAU - Wang, Hongwang
AU  - Wang H
AD  - Kansas State University, Department of Chemistry, CBC 201, Manhattan, KS 66506.
FAU - Shrestha, Tej B
AU  - Shrestha TB
FAU - Basel, Matthew T
AU  - Basel MT
FAU - Dani, Raj Kumar
AU  - Dani RK
FAU - Seo, Gwi-Moon
AU  - Seo GM
FAU - Balivada, Sivasai
AU  - Balivada S
FAU - Pyle, Marla M
AU  - Pyle MM
FAU - Prock, Heidy
AU  - Prock H
FAU - Koper, Olga B
AU  - Koper OB
FAU - Thapa, Prem S
AU  - Thapa PS
FAU - Moore, David
AU  - Moore D
FAU - Li, Ping
AU  - Li P
FAU - Chikan, Viktor
AU  - Chikan V
FAU - Troyer, Deryl L
AU  - Troyer DL
FAU - Bossmann, Stefan H
AU  - Bossmann SH
LA  - eng
PT  - Journal Article
DEP - 20120613
PL  - Germany
TA  - Beilstein J Nanotechnol
JT  - Beilstein journal of nanotechnology
JID - 101551563
PMC - PMC3388369
OTO - NOTNLM
OT  - SN38
OT  - cell-based delivery
OT  - chemotherapeutic prodrug
OT  - magnetic Fe/Fe3O4 nanoparticles
EDAT- 2012/09/28 06:00
MHDA- 2012/09/28 06:01
PMCR- 2012/06/13
CRDT- 2012/09/28 06:00
PHST- 2012/03/30 00:00 [received]
PHST- 2012/05/24 00:00 [accepted]
PHST- 2012/09/28 06:00 [entrez]
PHST- 2012/09/28 06:00 [pubmed]
PHST- 2012/09/28 06:01 [medline]
PHST- 2012/06/13 00:00 [pmc-release]
AID - 10.3762/bjnano.3.51 [doi]
PST - ppublish
SO  - Beilstein J Nanotechnol. 2012;3:444-55. doi: 10.3762/bjnano.3.51. Epub 2012 Jun 
      13.